Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1173 entries
Sorted by: Best Match Show Resources per page
Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial.

Clinical and experimental emergency medicine

Karimi N, Tavakoli M, Charati JY, Shamsizade M.
PMID: 29026887
Clin Exp Emerg Med. 2017 Sep 30;4(3):138-145. doi: 10.15441/ceem.16.199. eCollection 2017 Sep.

OBJECTIVE: Migraine headache is a chronic and disabling condition in adults. Some studies have investigated the efficacy of sodium valproate in the treatment of acute migraine, but the effectiveness and tolerability of intravenous valproate as abortive therapy remains unclear....

Cite
Karimi N, Tavakoli M, Charati JY, et al. Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial. Clin Exp Emerg Med. 2017;4(3):138-145doi: 10.15441/ceem.16.199.
Karimi, N., Tavakoli, M., Charati, J. Y., & Shamsizade, M. (2017). Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial. Clinical and experimental emergency medicine, 4(3), 138-145. https://doi.org/10.15441/ceem.16.199
Karimi, Narges, et al. "Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial." Clinical and experimental emergency medicine vol. 4,3 (2017): 138-145. doi: https://doi.org/10.15441/ceem.16.199
Karimi N, Tavakoli M, Charati JY, Shamsizade M. Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial. Clin Exp Emerg Med. 2017 Sep 30;4(3):138-145. doi: 10.15441/ceem.16.199. eCollection 2017 Sep. PMID: 29026887; PMCID: PMC5635457.
Copy Download .nbib Format: NLM
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study.

ERJ open research

Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP.
PMID: 27730152
ERJ Open Res. 2015 Oct 19;1(2). doi: 10.1183/23120541.00029-2015. eCollection 2015 Oct.

Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing.

Cite
Berghmans T, Lafitte JJ, Scherpereel A, et al. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Res. 2015;1(2)doi: 10.1183/23120541.00029-2015.
Berghmans, T., Lafitte, J. J., Scherpereel, A., Ameye, L., Paesmans, M., Meert, A. P., Colinet, B., Tulippe, C., Willems, L., Leclercq, N., Sculier, J. P. (2015). VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ open research, 1(2), . https://doi.org/10.1183/23120541.00029-2015
Berghmans, Thierry, et al. "VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study." ERJ open research vol. 1,2 (2015). doi: https://doi.org/10.1183/23120541.00029-2015
Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Res. 2015 Oct 19;1(2). doi: 10.1183/23120541.00029-2015. eCollection 2015 Oct. PMID: 27730152; PMCID: PMC5005117.
Copy Download .nbib Format: NLM
Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload.

Turkish journal of medical sciences

Liu Y, Li S, Zhang Z, Lv Z, Jiang H, Tan X, Liu F.
PMID: 29152949
Turk J Med Sci. 2017 Nov 13;47(5):1651-1660. doi: 10.3906/sag-1704-142.

Background/aim: Pressure overload induces cardiac remodelling and results in heart failure. Enhanced sympathetic outflow participates in the development of cardiac remodelling for the duration of pressure overload as an independent factor. Valproic acid has recently been shown to reduce...

Cite
Liu Y, Li S, Zhang Z, et al. Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload. Turk J Med Sci. 2017;47(5):1651-1660doi: 10.3906/sag-1704-142.
Liu, Y., Li, S., Zhang, Z., Lv, Z., Jiang, H., Tan, X., & Liu, F. (2017). Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload. Turkish journal of medical sciences, 47(5), 1651-1660. https://doi.org/10.3906/sag-1704-142
Liu, Yang, et al. "Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload." Turkish journal of medical sciences vol. 47,5 (2017): 1651-1660. doi: https://doi.org/10.3906/sag-1704-142
Liu Y, Li S, Zhang Z, Lv Z, Jiang H, Tan X, Liu F. Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload. Turk J Med Sci. 2017 Nov 13;47(5):1651-1660. doi: 10.3906/sag-1704-142. PMID: 29152949.
Copy Download .nbib Format: NLM
Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Kute VB, Trivedi HL, Shah PR, Gumber MR, Patel HV, Vanikar AV.
PMID: 24339647
Indian J Crit Care Med. 2013 Sep;17(5):318-20. doi: 10.4103/0972-5229.120329.

First Report of the Indian Chronic Kidney Disease (CKD) Registry showed that patient with CKD in India more frequently presented in Stage V. Many patients have uncontrolled hypertension and uremia due to noncompliance or non affordability of renal replacement...

Cite
Kute VB, Trivedi HL, Shah PR, et al. Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease. Indian J Crit Care Med. 2013;17(5):318-20doi: 10.4103/0972-5229.120329.
Kute, V. B., Trivedi, H. L., Shah, P. R., Gumber, M. R., Patel, H. V., & Vanikar, A. V. (2013). Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 17(5), 318-20. https://doi.org/10.4103/0972-5229.120329
Kute, Vivek B, et al. "Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 17,5 (2013): 318-20. doi: https://doi.org/10.4103/0972-5229.120329
Kute VB, Trivedi HL, Shah PR, Gumber MR, Patel HV, Vanikar AV. Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease. Indian J Crit Care Med. 2013 Sep;17(5):318-20. doi: 10.4103/0972-5229.120329. PMID: 24339647; PMCID: PMC3841498.
Copy Download .nbib Format: NLM
Differential improvement of the sleep quality among patients with juvenile myoclonic epilepsy with valproic acid: A longitudinal sleep questionnaire-based study.

Annals of Indian Academy of Neurology

Nayak C, Sinha S, Ramachandraiah CT, Nagappa M, Thennarasu K, Taly AB, Satishchandra P.
PMID: 26713010
Ann Indian Acad Neurol. 2015 Oct-Dec;18(4):403-7. doi: 10.4103/0972-2327.165472.

OBJECTIVES: The aim of this study was to assess the effect of sodium valproic acid (SVA) on the sleep quality of patients with juvenile myoclonic epilepsy (JME).MATERIALS AND METHODS: Standardized sleep questionnaires viz. Epworth Sleepiness Scale (ESS) and Pittsburgh...

Cite
Nayak C, Sinha S, Ramachandraiah CT, et al. Differential improvement of the sleep quality among patients with juvenile myoclonic epilepsy with valproic acid: A longitudinal sleep questionnaire-based study. Ann Indian Acad Neurol. 2015;18(4):403-7doi: 10.4103/0972-2327.165472.
Nayak, C., Sinha, S., Ramachandraiah, C. T., Nagappa, M., Thennarasu, K., Taly, A. B., & Satishchandra, P. (2015). Differential improvement of the sleep quality among patients with juvenile myoclonic epilepsy with valproic acid: A longitudinal sleep questionnaire-based study. Annals of Indian Academy of Neurology, 18(4), 403-7. https://doi.org/10.4103/0972-2327.165472
Nayak, Chetan, et al. "Differential improvement of the sleep quality among patients with juvenile myoclonic epilepsy with valproic acid: A longitudinal sleep questionnaire-based study." Annals of Indian Academy of Neurology vol. 18,4 (2015): 403-7. doi: https://doi.org/10.4103/0972-2327.165472
Nayak C, Sinha S, Ramachandraiah CT, Nagappa M, Thennarasu K, Taly AB, Satishchandra P. Differential improvement of the sleep quality among patients with juvenile myoclonic epilepsy with valproic acid: A longitudinal sleep questionnaire-based study. Ann Indian Acad Neurol. 2015 Oct-Dec;18(4):403-7. doi: 10.4103/0972-2327.165472. PMID: 26713010; PMCID: PMC4683877.
Copy Download .nbib Format: NLM
In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation.

Cancer research and treatment

Chie EK, Shin JH, Kim JH, Kim HJ, Kim IA, Kim IH.
PMID: 25600060
Cancer Res Treat. 2015 Jul;47(3):527-33. doi: 10.4143/crt.2014.026. Epub 2014 Nov 24.

PURPOSE: This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.MATERIALS AND METHODS: Radiosensitization effect of valproic acid was tested for the A549 cell line and...

Cite
Chie EK, Shin JH, Kim JH, et al. In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation. Cancer Res Treat. 2014;47(3):527-33doi: 10.4143/crt.2014.026.
Chie, E. K., Shin, J. H., Kim, J. H., Kim, H. J., Kim, I. A., & Kim, I. H. (2015). In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation. Cancer research and treatment, 47(3), 527-33. https://doi.org/10.4143/crt.2014.026
Chie, Eui Kyu, et al. "In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation." Cancer research and treatment vol. 47,3 (2015): 527-33. doi: https://doi.org/10.4143/crt.2014.026
Chie EK, Shin JH, Kim JH, Kim HJ, Kim IA, Kim IH. In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation. Cancer Res Treat. 2015 Jul;47(3):527-33. doi: 10.4143/crt.2014.026. Epub 2014 Nov 24. PMID: 25600060; PMCID: PMC4506108.
Copy Download .nbib Format: NLM
Interaction between carbenoxolone and valproic acid on pentylenetetrazole kindling model of epilepsy.

International journal of clinical and experimental medicine

Sefil F, Arık AE, Acar MD, Bostancı MÖ, Bagirici F, Kozan R.
PMID: 26379841
Int J Clin Exp Med. 2015 Jul 15;8(7):10508-14. eCollection 2015.

Gap junctions play an important role in the synchronized neuronal discharges. The main reason of the epileptic seizures is disruption of this synchronization. Therefore, the aim of the present study is to explore the combination valproic acid with carbenoxolone...

Cite
Sefil F, Arık AE, Acar MD, et al. Interaction between carbenoxolone and valproic acid on pentylenetetrazole kindling model of epilepsy. Int J Clin Exp Med. 2015;8(7):10508-14
Sefil, F., Arık, A. E., Acar, M. D., Bostancı, M. �. �., Bagirici, F., & Kozan, R. (2015). Interaction between carbenoxolone and valproic acid on pentylenetetrazole kindling model of epilepsy. International journal of clinical and experimental medicine, 8(7), 10508-14.
Sefil, Fatih, et al. "Interaction between carbenoxolone and valproic acid on pentylenetetrazole kindling model of epilepsy." International journal of clinical and experimental medicine vol. 8,7 (2015): 10508-14.
Sefil F, Arık AE, Acar MD, Bostancı MÖ, Bagirici F, Kozan R. Interaction between carbenoxolone and valproic acid on pentylenetetrazole kindling model of epilepsy. Int J Clin Exp Med. 2015 Jul 15;8(7):10508-14. eCollection 2015. PMID: 26379841; PMCID: PMC4565224.
Copy Download .nbib Format: NLM
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Pharmaceuticals (Basel, Switzerland)

Saruwatari J, Ishitsu T, Nakagawa K.
PMID: 27713373
Pharmaceuticals (Basel). 2010 Aug 20;3(8):2709-2732. doi: 10.3390/ph3082709.

Genetic polymorphisms in the genes that encode drug-metabolizing enzymes are implicated in the inter-individual variability in the pharmacokinetics and pharmaco-dynamics of antiepileptic drugs (AEDs). However, the clinical impact of these polymorphisms on AED therapy still remains controversial. The defective...

Cite
Saruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel). 2010;3(8):2709-2732doi: 10.3390/ph3082709.
Saruwatari, J., Ishitsu, T., & Nakagawa, K. (2010). Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel, Switzerland), 3(8), 2709-2732. https://doi.org/10.3390/ph3082709
Saruwatari, Junji, et al. "Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy." Pharmaceuticals (Basel, Switzerland) vol. 3,8 (2010): 2709-2732. doi: https://doi.org/10.3390/ph3082709
Saruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel). 2010 Aug 20;3(8):2709-2732. doi: 10.3390/ph3082709. PMID: 27713373; PMCID: PMC4033946.
Copy Download .nbib Format: NLM
Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response.

Epigenetics & chromatin

Halsall JA, Turan N, Wiersma M, Turner BM.
PMID: 26380582
Epigenetics Chromatin. 2015 Sep 16;8:29. doi: 10.1186/s13072-015-0021-9. eCollection 2015.

BACKGROUND: The genome-wide hyperacetylation of chromatin caused by histone deacetylase inhibitors (HDACi) is surprisingly well tolerated by most eukaryotic cells. The homeostatic mechanisms that underlie this tolerance are unknown. Here we identify the transcriptional and epigenomic changes that constitute...

Cite
Halsall JA, Turan N, Wiersma M, et al. Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics Chromatin. 2015;8:29doi: 10.1186/s13072-015-0021-9.
Halsall, J. A., Turan, N., Wiersma, M., & Turner, B. M. (2015). Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics & chromatin, 829. https://doi.org/10.1186/s13072-015-0021-9
Halsall, John A, et al. "Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response." Epigenetics & chromatin vol. 8 (2015): 29. doi: https://doi.org/10.1186/s13072-015-0021-9
Halsall JA, Turan N, Wiersma M, Turner BM. Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics Chromatin. 2015 Sep 16;8:29. doi: 10.1186/s13072-015-0021-9. eCollection 2015. PMID: 26380582; PMCID: PMC4572612.
Copy Download .nbib Format: NLM
Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy.

Frontiers in neurology

Rakitin A, Kõks S, Reimann E, Prans E, Haldre S.
PMID: 26379622
Front Neurol. 2015 Aug 31;6:188. doi: 10.3389/fneur.2015.00188. eCollection 2015.

Valproic acid (VPA) is a widely used antiepileptic drug with a broad range of effects and broad clinical efficacy. As a well-known histone deacetylase (HDAC) inhibitor, VPA regulates epigenetic programming by altering the expression of many genes. The aim...

Cite
Rakitin A, Kõks S, Reimann E, et al. Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy. Front Neurol. 2015;6:188doi: 10.3389/fneur.2015.00188.
Rakitin, A., Kõks, S., Reimann, E., Prans, E., & Haldre, S. (2015). Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy. Frontiers in neurology, 6188. https://doi.org/10.3389/fneur.2015.00188
Rakitin, Aleksei, et al. "Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy." Frontiers in neurology vol. 6 (2015): 188. doi: https://doi.org/10.3389/fneur.2015.00188
Rakitin A, Kõks S, Reimann E, Prans E, Haldre S. Changes in the Peripheral Blood Gene Expression Profile Induced by 3 Months of Valproate Treatment in Patients with Newly Diagnosed Epilepsy. Front Neurol. 2015 Aug 31;6:188. doi: 10.3389/fneur.2015.00188. eCollection 2015. PMID: 26379622; PMCID: PMC4553897.
Copy Download .nbib Format: NLM
The investigation of EEG specificity in epileptic children during Depakine therapy.

The International journal of neuroscience

Khachidze I, Gugushvili M, Makashvili M, Maloletnev V.
PMID: 26279359
Int J Neurosci. 2015 Aug 17;1-23. Epub 2015 Aug 17.

BACKGROUND: Antiepileptic drug (AED) therapy in epileptic children can be optimized via an anticipation of AED efficacy during early stages of therapy. We hypothesize that the comprehensive EEG evaluation can determine AED efficacy in epileptic children. Thus, this study...

Cite
Khachidze I, Gugushvili M, Makashvili M, et al. The investigation of EEG specificity in epileptic children during Depakine therapy. Int J Neurosci. 2015;1-23
Khachidze, I., Gugushvili, M., Makashvili, M., & Maloletnev, V. (2015). The investigation of EEG specificity in epileptic children during Depakine therapy. The International journal of neuroscience, 1-23.
Khachidze, Irma, et al. "The investigation of EEG specificity in epileptic children during Depakine therapy." The International journal of neuroscience vol. (2015): 1-23.
Khachidze I, Gugushvili M, Makashvili M, Maloletnev V. The investigation of EEG specificity in epileptic children during Depakine therapy. Int J Neurosci. 2015 Aug 17;1-23. Epub 2015 Aug 17. PMID: 26279359.
Copy Download .nbib Format: NLM
Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration.

International journal of molecular sciences

Kimura A, Namekata K, Guo X, Harada C, Harada T.
PMID: 27657046
Int J Mol Sci. 2016 Sep 20;17(9). doi: 10.3390/ijms17091584.

Neurotrophic factors play key roles in the development and survival of neurons. The potent neuroprotective effects of neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-line derived neurotrophic factor (GDNF) and nerve growth factor (NGF),...

Cite
Kimura A, Namekata K, Guo X, et al. Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration. Int J Mol Sci. 2016;17(9)doi: 10.3390/ijms17091584.
Kimura, A., Namekata, K., Guo, X., Harada, C., & Harada, T. (2016). Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration. International journal of molecular sciences, 17(9), . https://doi.org/10.3390/ijms17091584
Kimura, Atsuko, et al. "Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration." International journal of molecular sciences vol. 17,9 (2016). doi: https://doi.org/10.3390/ijms17091584
Kimura A, Namekata K, Guo X, Harada C, Harada T. Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration. Int J Mol Sci. 2016 Sep 20;17(9). doi: 10.3390/ijms17091584. PMID: 27657046; PMCID: PMC5037849.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1173 entries